Fate Therapeutics gets RMAT status from FDA for Lupus treatment
Source: SeekingAlpha
2025-04-14 11:34:06 ET
More on Fate Therapeutics
- Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap
- Seeking Alpha’s Quant Rating on Fate Therapeutics
- Historical earnings data for Fate Therapeutics
- Financial information for Fate Therapeutics
Read the full article on Seeking Alpha
For further details see:
Fate Therapeutics gets RMAT status from FDA for Lupus treatment
Fate Therapeutics Inc.
NASDAQ: FATE
FATE Trading
-9.85% G/L:
$1.785 Last:
567,256 Volume:
$1.86 Open:
FATE Latest News
May 13, 2026 08:30:00 am
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesMay 11, 2026 08:30:00 am
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual MeetingFATE Stock Data
$128,041,041
108,996,378
1.54%
45
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
